Actively Recruiting

Age: 65Years - 100Years
All Genders
ID05459597

Population Pharmacokinetics, Effectiveness and Safety of Antiepileptic Drugs in Elderly Patients

Led by Wei Zhao · Updated on 2022-07-15

500

Participants Needed

1

Research Sites

13 weeks

Total Duration

On this page

Sponsors

W

Wei Zhao

Lead Sponsor

Q

Qianfoshan Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying elderly patients aged 65 to 100 years who have epilepsy to understand how antiepileptic drugs like phenytoin, carbamazepine, lamotrigine, levetiracetam, and perampanel behave in the body. The study aims to evaluate how effective and safe these drugs are in this population and to recommend optimized dosage plans. Participants receive antiepileptic drugs as part of their routine treatment, with the specific drug choice depending on clinical practice. This observational study monitors patients without altering their treatment but collects detailed information on drug levels and effects. During the study, researchers measure drug concentrations at different times after oral administration to track how the medication is processed. They also record any adverse drug reactions and seizure frequency over an average period of 14 days. The study started in 2021 and will continue through June 2028, involving ongoing assessments to better understand treatment outcomes in elderly patients with epilepsy.

CONDITIONS

Brief Title

Antiepileptic Drugs in Elderly Patients

Who Can Participate

Age: 65Years - 100Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 65 years old
  • Diagnosed with epilepsy
  • Using antiepileptic drugs for treatment
Not Eligible

You will not qualify if you...

  • Patients who are expected to die within 48 hours
  • Patients with allergy to antiepileptic drugs
  • Patients receiving other investigational drugs
  • Other factors that the researcher considers unsuitable for inclusion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Approximately 14 days

Participants who use antiepileptic drugs as part of routine treatment are observed for drug concentrations and seizure frequency.

Visits occur within 0 to 10 hours after drug administration and at 1 to 2 hours before the next dose, plus monitoring throughout the treatment period

Trial Site Locations

Total: 1 location

1

Wei Zhao

Jinan, Shandong, China

Actively Recruiting

Loading map...

Research Team

W

Wei Zhao

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Study of the New 2014 Epilepsy Definition's Effect on Diagno...

Seizure, Epileptic

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here